BioMed Nexus Daily Updates

Your essential biotech, medtech, and pharma recap, no noise, just what matters.

Tuesday, November 17, 2026

📌 TL;DR

  • Helus Pharma's Phase 3 APPROACH study met its primary endpoint: HLP003, a deuterated psilocin added to a stable antidepressant, cut MADRS scores 19.5 points versus 11.9 for placebo at week 6 (p<0.0001), with significance from Day 2 through week 12.

  • Remission at week 6 was 50.9% on HLP003 versus 18.2% on placebo; the company reported three treatment related serious adverse events and no new safety signals.

  • Summit's first session after the ivonescimab CRL closed at 11.82, down 16.5%, with no resubmission plan or timeline on record.

  • Novo's REDEFINE 1 post hoc tied early response to CagriSema to 25.4% weight loss at week 68, and the release confirmed the FDA decision on CagriSema is expected in Q4 2026.

  • BioXcel has announced nothing either way on the Igalmi at home sNDA, now two days past the November 14 action date.

  • Tape: HELP −13.5% on its topline day, AMLX −8.2% first session post data, XBI −3.1%.

⚡ Executive Takeaway

The market just told you what it pays for, and it is not data. Three companies came into Monday holding positive Phase 3 results, and all three closed lower. Outside the new issue names, the only green on our board was Lexeo, up 12.5 percent, and what Lexeo announced was only secondarily data. The FDA told the company it is open to guideline defined NSVT, a counted arrhythmia measure, as the primary surrogate endpoint for an accelerated approval study of its gene therapy in PKP2 arrhythmogenic cardiomyopathy. On the same weekend the agency refused Summit for want of a counted survival statistic, the market's single reward went to the sponsor that secured agreement on what gets counted. That is the through line running in both directions. Where the count is settled, capital shows up before the pivotal study even starts. Where it is not settled, an effect size of 0.653 and a p value under 0.0001 bought a double digit decline into a falling tape. Watch what gets funded this week: endpoints, not molecules.

🧠 A Deuterated Psilocin Just Won Its Phase 3

Helus Pharma's HLP003 beat placebo by 7.6 MADRS points at week 6 with separation from Day 2, and the stock closed down 13.5% anyway. HELP

APPROACH randomized 222 adults with moderate to severe major depressive disorder to HLP003 or placebo on top of a stable antidepressant. The margin held everywhere the protocol looked: remission nearly tripled placebo at week 6, and the week 12 key secondary stayed significant, the durability question that has dogged rapid acting antidepressants. Helus, the company formerly known as Cybin, reported three treatment related serious adverse events and no new safety signals, with most adverse events limited to the day of dosing. The release names no NDA date; the second pivotal, EMBRACE, reads out in the fourth quarter of 2027. Outside investigator Roger McIntyre called the results a new benchmark for adjunctive treatment in the company's release. The table shows why.

APPROACH endpoint

HLP003 (n=112)

Placebo (n=110)

MADRS reduction, week 6

19.5 points

11.9 points

Remission, week 6

50.9%

18.2%

Remission, week 12

40.2%

15.5%

Response, Day 2

50.0%

23.6%

🚫 Summit's Clearing Price: 11.82

The first session after the ivonescimab CRL closed at 11.82, down 16.5%, and the US story now prices off HARMONi-3 alone. SMMT

Sunday's letter said the quiet part in writing: without a statistically significant overall survival win, the PFS benefit does not support approval, and no approved regimen in this setting has one either. Chairman Robert Duggan's answer, five positive Phase 3 studies and nothing changes, met a market that disagreed by sixteen and a half points. The release carries no resubmission plan or timeline, which is the detail we are watching: a Type A meeting disclosure would be the first sign of a defined path back. Our call from Monday's edition stands, a HARMONi-3 PFS win is a stock event, not an approval event, and the CRL itself is the agency's endorsement of that distinction. Four sessions have now taken the stock down 29% from its November 11 close, our arithmetic.

💉 ObesityWeek's Bill Came Due

Amylyx gave back 8.2% and Viking 8.3% in their first sessions after positive data, while Novo put a Q4 2026 FDA date on CagriSema and closed flat. AMLX | VKTX | NVO

Nothing in either dataset changed over the weekend. Amylyx's avexitide still cut composite hypoglycemia events 55% with an NDA coming by year end; Viking's subcutaneous VK2735 still moved 74% of participants down at least one BMI category, with its Phase 3s completing in 2027. The new information was Novo's: a REDEFINE 1 post hoc showing early responders, the 67.8% of the CagriSema arm with at least 5% weight loss by week 8, averaged 25.4% loss at week 68 against 17.8% for delayed responders, observed and hypothesis generating, but exactly the sorting rule a payer can write into continuation criteria. The lower dose REDEFINE 9 trial added about 21% average weight loss, per Novo's release headline, published in The Lancet Diabetes and Endocrinology. Rhythm, meanwhile, has released nothing at the meeting through Monday night, its newest release still the November 4 NICE guidance, and fell 6.6%. The conference closes today.

🫀 The One Green Name Got Paid for an Endpoint

Lexeo rose 12.5% after the FDA signaled openness to a counted arrhythmia measure as the primary surrogate endpoint for an accelerated approval study of LX2020. LXEO

The data were real but early: in HEROIC-PKP2, the seven high dose participants showed an 80% mean reduction in nonsustained ventricular tachycardia and a 44% cut in PVC burden, ten patients dosed in all, no discontinuations, and one previously disclosed Grade 3 event that resolved. What moved the stock is what the FDA is open to counting: guideline defined NSVT as the primary surrogate in a pivotal study of the gene therapy in PKP2 arrhythmogenic cardiomyopathy, expected to start in the second half of 2027 with the design settled in the first half. With $219.1 million of cash running into 2028, Lexeo can reach that start without asking the market for anything. On a tape that sold three Phase 3 wins, an agreed denominator was worth twelve and a half points.

💰 The Ends Still Pay

  • Windward added 5.4% to close at 30.04, 76.7% above its $17.00 IPO price, our arithmetic, with the greenshoe still unexercised as far as the record shows, and Surrozen held above its $31.67 print at 32.32 on the day its closing was due. WWB | SRZN

  • The middle kept paying for the privilege: Rezolute sat at 3.58 against its $3.87 print and Vir fell a further 3.8% for a third straight session below its $10.00 offer; none of the four companies due to close financings on or about Monday had posted a closing release by Monday night (we checked Rezolute's investor page directly; closings can complete without one, so the watch stays open rather than graded). RZLT | VIR

  • Innovent received a positive CHMP opinion for sintilimab (Zybrivo) in first line nonsquamous non small cell lung cancer, per the company's release, moving a Chinese PD-1 toward the EU market, while China's 2026 reimbursement list added Zai Lab's KarXT and VYVGART Hytrulo and seven Innovent products including mazdutide; Zai's US shares fell 4.6%. ZLAB

  • China's MOFCOM comment period on the draft biotech export control catalogue closed November 15, and no final catalogue has been published that we could find.

👀 What To Watch Today

  • Tue, Nov 17: ObesityWeek concludes, with Corbus' CANYON-1 late breaker, Corbus

  • Thu, Nov 19: Biohaven's BHV-1530 oral presentation at EORTC-NCI-AACR, Biohaven

  • Sun, Nov 22: Capricor's deramiocel action date; the practical window opens Friday, Capricor

📖 In Today's Full Analysis

Be sure to read the full article for all the details, including:

  • The complete APPROACH dataset, endpoint by endpoint, with the trial design and the safety fine print

  • Summit's four session slide in numbers and what the CRL left unanswered

  • The CagriSema early responder tables and the Q4 2026 decision setup

  • Lexeo's LX2020 data, the FDA's surrogate endpoint position, and the day's movers with context

🔒 BioMed Nexus Pro

In Today's Pro Brief...

  • 🧠 The price of a clean win: where the data premium went, and what it now takes to get paid on results day

  • 💊 Summit at 11.82: the arithmetic the CRL left behind and the one number that reopens the US story

  • 📊 The payer tool hiding in Novo's post hoc: how an early responder rule becomes coverage language

  • 🎯 Plus the week's coming catalysts, with the full calendar returning in Friday's edition